Atheris Laboratories, Debiopharm Group, and Ecole Polytechnique Fédérale de Lausanne

Atheris is a Swiss biotechnology company specializing in the discovery and development of novel drug candidates derived from animal venoms. Utilizing its proprietary Melusine platform, the company explores a vast library of venom-derived peptides and proteins to identify high-affinity leads for complex biological targets such as ion channels and G protein-coupled receptors. Atheris operates primarily through a partnership-driven model, collaborating with major pharmaceutical companies like Debiopharm and academic institutions like EPFL to advance its discovery programs. Its research focuses on high-need therapeutic areas including chronic pain, neurological disorders, and metabolic diseases.